Latest "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" News Stories

11:06 EST 20th January 2017 | BioPortfolio

Here are the most relevant search results for "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" found in our extensive news archives from over 250 global news sources.

More Information about Fluorouracil Leukovorin bevacizumab Colorectal Cancer on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Fluorouracil Leukovorin bevacizumab Colorectal Cancer for you to read. Along with our medical data and news we also list Fluorouracil Leukovorin bevacizumab Colorectal Cancer Clinical Trials, which are updated daily. BioPortfolio also has a large database of Fluorouracil Leukovorin bevacizumab Colorectal Cancer Companies for you to search.

Showing "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" News Articles 1–25 of 17,000+

Extremely Relevant

Adjuvant Bevacizumab for Colorectal Cancer?

Adding bevacizumab to capecitabine did not improve survival for patients with stage III or high-risk stage II disease.

Middle-Aged Man With Acute Thrombocytopenia Subsequent to Fluorouracil and Oxaliplatin Chemotherapy for Colorectal Cancer

A 44-year-old patient with a history of stage IIB colorectal cancer at the hepatic flexure, invading the duodenum and pancreas, was initially diagnosed in September 2005 and received modified Whipple surgery and 8 cycles of adjuvant chemotherapy with capecitabine and oxaliplatin every 3 weeks.

Therapy: No benefit for adjuvant capecitabine plus bevacizumab in colorectal cancer

Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer

Epigenomics alternations and dynamic transcriptional changes in responses to 5-fluorouracil stimulation reveal mechanisms of acquired drug resistance of colorectal cancer cells

CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy

FOLFOX Equals or Betters Epirubicin, Cisplatin, and Fluorouracil in Esophagogastric Cancer

Adding epirubicin to fluorouracil/platinum-based chemotherapy resulted in greater toxicity and no clear improvement in response.

FDA approves bevacizumab with chemotherapy for platinum-sensitive ovarian cancer

The U.S. Food and Drug Administration (FDA) has approved bevacizumab, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by bevacizumab alone, for the treatment of patients with...

BRIEF-Amgen says new retrospective analyses confirm Vectibix treatment provided survival benefit over chemotherapy with or without Bevacizumab

* New retrospective analyses confirm Vectibix (panitumumab) treatment provided survival benefit over chemotherapy with or without bevacizumab in metastatic colorectal cancer patients with tumors of left-sided origin Source text for Eikon: Further ...

How mouth microbes may worsen colorectal cancer

Bacteria commonly found in the mouth have been recently shown to worsen colorectal cancer in animals, but it has not been clear how these microbes make their way to the gut in the first place. A study published August 10 in Cell Host & Microbe sheds light on this question, revealing that oral microbes called fusobacteria may use the bloodstream to reach colorectal tumors. The findings also show ex...

Medical News Today: Colorectal cancer screening initiative shows promise

The Ohio State University have trialed a colorectal cancer screening initiative for relatives of colorectal cancer patients. The results are promising.

Retinoic acid suppresses colorectal cancer development

Retinoic acid, a compound derived in the body from vitamin A, plays a critical role in suppressing colorectal cancer in mice and humans, according to new research. Mice with colorectal cancer have lower-than-normal levels of the metabolite in their gut,...

Fecal Fat Points to Early Presence of Colorectal Cancer

Colorectal cancer (CRC) remains a leading cause of cancer mortality worldwide, and therefore more accessible screening tests are urgently needed...

Blood Test for Colorectal Cancer Recurrence Proves Highly Sensitive

When diagnosed early, before cancer has spread, the relative five-year survival rate for colorectal cancer (CRC) is 90%, but only...

Hispanic men in California need more screening for colorectal cancer

Colorectal cancer incidence and mortality rates in California have decreased markedly for men and women in all major racial-ethnic groups since 1990, except for Hispanic men. Colorectal cancer rates for Hispanic men have remained relatively the same, a...

FDA Approves Avastin® (Bevacizumab) Plus Chemotherapy for Treatment of Advanced Ovarian Cancer

Genentech announced that the U.S. Food and Drug Administration (FDA) has approved Avastin® (bevacizumab) either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone, for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Women are said to...

Metabolite that promotes cancer cell transformation and colorectal cancer spread identified

Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial–mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread. The finding highlights the value of targeting D-2HG to establish new therapeutic approaches against...

Clinical Genomics’ blood test detects twice the number of colorectal cancer recurrence cases than CEA testing

Clinical Genomics, a private company developing innovative diagnostic tools for colorectal cancer, today announced that data supporting its two-gene circulating tumor DNA (ctDNA) blood test for post-surgical monitoring of colorectal cancer (CRC) recurrence have been published online by Cancer Medicine, and will appear in the October issue.

BRIEF-Genentech- says U.S. FDA has approved Avastin Bevacizumab

* FDA approves Genentech's Avastin (Bevacizumab) plus chemotherapy for a specific type of advanced ovarian cancer Source text for Eikon: Further company coverage:


NCCN Guidelines® Recommend SIR-Spheres® Y-90 Resin Microspheres for the Treatment of Metastatic Colorectal Cancer

SIR-Spheres® Y-90 microspheres have just been added as a new treatment option in the latest National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for colon cancer and rectal cancer. Nearly 140,000 Americans are diagnosed with colorectal cancer every year1, and more than 50% will have their cancer spread to their liver.2 This gives patients with cancer [̷...

Answering the call for quality colorectal cancer patient info

Patients depend on the Internet for health information, but when it comes to colorectal cancer, currently available resources are not meeting their needs.

Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases

Poor responses of liver metastases to the anti-angiogenic agent bevacizumab in colorectal and breast cancer patients correlate with tumor co-option of pre-existing blood vessels, a mechanism of tumor resistance that might be targeted by inhibition of cancer cell motility.

FDA Approves Avastin (bevacizumab) Plus Chemotherapy for a Specific Type of Advanced Ovarian Cancer

South San Francisco, CA -- December 6, 2016 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Avastin (bevacizumab), either in combination with...

Colorectal Cancer Screening Recommendations

To the Editor The US Preventive Services Task Force (USPSTF) recommendation statement on colorectal cancer screening recommends screening for black adults beginning at age 50 years, in contrast to the American College of Gastroenterology guidelines for colorectal cancer screening in 2009 that recommend screening beginning at age 45 years. The USPSTF report acknowledged that the black population ha...

Roche, Merck, AstraZeneca and Abbott to Invest Heavily in Colorectal Cancer Studies

HYDERABAD, India, September 30, 2016 /PRNewswire/ -- Mordor Intelligence announces the publication of their research report on the colorectal cancer market. The report titled, "Global Colorectal Cancer Diagnostics and Therapeutics Market - Growth, Trends & Forecast," discusses the current landscape and outlook of the market. The global colorectal cancer market is estimated to account USD 8 b...

Quick Search

News Quicklinks